Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2015-06 Issue:6 Volume:16 Page:619-629
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Li Jin,Qin Shukui,Xu Ruihua,Yau Thomas C C,Ma Brigette,Pan Hongming,Xu Jianming,Bai Yuxian,Chi Yihebali,Wang Liwei,Yeh Kun-Huei,Bi Feng,Cheng Ying,Le Anh Tuan,Lin Jen-Kou,Liu Tianshu,Ma Dong,Kappeler Christian,Kalmus Joachim,Kim Tae Won

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. International trends in colorectal cancer incidence rates;Center;Cancer Epidemiol Biomarkers Prev,2009

2. Adaptation of international guidelines for metastatic colorectal cancer: an Asian consensus;Cheng;Clin Colorectal Cancer,2014

3. Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012;Ku;Lancet Oncol,2012

4. Trends in colorectal cancer in the south of the Netherlands 1975–2007: rectal cancer survival levels with colon cancer survival;Lemmens;Acta Oncol,2010

5. Improving outcomes in colorectal cancer: where do we go from here?;Van Cutsem;Eur J Cancer,2013

Cited by 599 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?;Critical Reviews in Oncology/Hematology;2024-10

2. Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy;Frontiers in Oncology;2024-08-20

3. Exploratory Study Identifies Matrix Metalloproteinase-14 and -9 as Potential Biomarkers of Regorafenib Efficacy in Metastatic Colorectal Cancer;Cancers;2024-08-15

4. Efficacy of immune checkpoint inhibitors combined with bevacizumab in MSS/pMMR advanced colorectal cancer after first-line treatment failure;Frontiers in Oncology;2024-08-12

5. Real-world dosing patterns of regorafenib for patients with metastatic colorectal cancer in Spain: the RE-SEARCH study;Clinical and Translational Oncology;2024-08-11